Do TET2 and ASXL1 Mutations Change Polycythemia Vera Risk?

When you are diagnosed with Polycythemia Vera (PV), the JAK2 mutation is typically the primary genetic driver that causes the disease. However, advanced genetic testing—often called Next-Generation Sequencing (NGS)—can reveal other mutations in your blood cells, such as TET2 and ASXL1 ^[1]. These are acquired (somatic) changes, meaning they develop over your lifetime and are generally not passed down to your children ^[2]. While JAK2 is the key driver in most PV, these additional mutations can arise either before or after the JAK2 mutation develops ^[2]. Doctors look for these extra mutations because they provide clues about how your PV might behave in the long term, helping your care team individualize your discussions about risk and monitoring ^[3].

What Are TET2 and ASXL1?

TET2 and ASXL1 belong to a group of genes that help control how other genes are turned on and off in your cells (a process called epigenetic regulation) ^[2]. While the JAK2 mutation acts like a stuck accelerator causing your body to make too many red blood cells, TET2 and ASXL1 mutations change the environment in your bone marrow. This can give certain blood-forming cells a growth advantage over others ^[2].

It is common to find these mutations alongside JAK2, though the exact rates vary depending on the type of test used and the group of patients studied. Some research suggests more than half of PV patients have at least one additional genetic mutation, with TET2 and ASXL1 being the most frequent ^[1][3].

Sometimes, these mutations develop in older adults who do not have a blood cancer. This is known as Clonal Hematopoiesis of Indeterminate Potential (CHIP), which is an age-related change in blood cells ^[4]. If an NGS test finds one of these mutations, your doctor will look at the exact variant and the rest of your clinical picture to determine if it is part of your PV or simply related to age ^[4][5].

Why Do These Mutations Matter?

Finding a TET2 or ASXL1 mutation does not change your diagnosis—you still have PV ^[5]. However, they provide your hematologist with a deeper understanding of your disease.

Assessing the Risk of Progression

The main reason doctors check for these additional mutations is to understand the risk of the disease changing over time. In PV, there is a risk that the condition can progress to myelofibrosis (scarring of the bone marrow) or, rarely, to acute myeloid leukemia (AML) ^[6][7].

• ASXL1: In population-level studies, ASXL1 is generally associated with a higher risk profile ^[3]. These studies show that groups of patients with an ASXL1 mutation have a higher risk of disease progression and shorter overall survival compared to those without it ^[8][3]. However, a positive ASXL1 result is not a personal timeline or a guarantee of progression; your individual risk depends heavily on your age, blood counts, and how well you respond to treatment ^[1].
• TET2: The impact of TET2 is less clear. While it is very common, it does not consistently show the same high-risk profile for progression as ASXL1 ^[3]. Some studies have explored whether TET2 increases the risk of blood clots, but the evidence is mixed and inconsistent ^[4][9]. Because of this uncertainty, a TET2 mutation alone is not used to make decisions about blood clot prevention ^[10].

Personalized Discussions and Care

Knowing whether you have these mutations allows your doctor to have a more personalized discussion with you. If you have a mutation like ASXL1, your doctor might use that information, alongside your symptoms and spleen size, to determine how closely you should be monitored ^[1]. There is no universally accepted monitoring schedule based solely on TET2 or ASXL1, so your follow-up will be tailored to your specific needs ^[11].

Importantly, finding one of these mutations does not automatically mean your treatment will change right now ^[11]. The core treatments for PV are still based on established factors like your age and history of blood clots:

• Therapeutic phlebotomy (blood removal) is often used to keep your hematocrit (the percentage of red cells in your blood) below 45% ^[12].
• Low-dose aspirin is commonly used to prevent clots, but only if it is safe for you (it can increase bleeding risk and is not for everyone) ^[1].
• Cytoreductive medications (like hydroxyurea or interferons) may be prescribed to control blood counts, depending on your overall risk and how you tolerate them ^[1].

Extended genetic testing like NGS is an evolving area of PV care and is not yet part of standard treatment guidelines for every patient ^[11]. Never start or stop medications based on a genetic test result without speaking to your care team ^[11].

🚨 When to Seek Immediate Medical Help
PV increases your risk of blood clots. Do not wait for a routine appointment if you experience signs of a severe clot, heart attack, or stroke. Seek emergency care immediately if you have:

• Sudden chest pain or severe shortness of breath
• Sudden weakness or numbness, especially on one side of the face or body
• Trouble speaking or understanding speech
• Sudden vision changes or a severe, unusual headache
• A painful, red, or swollen leg